Advertisement
Canada markets close in 1 hour 11 minutes

  • S&P/TSX

    21,875.85
    +2.13 (+0.01%)
     

  • S&P 500

    5,034.91
    -36.72 (-0.72%)
     

  • DOW

    37,987.88
    -473.04 (-1.23%)
     

  • CAD/USD

    0.7318
    +0.0021 (+0.28%)
     

  • CRUDE OIL

    83.54
    +0.73 (+0.88%)
     

  • Bitcoin CAD

    88,199.41
    +216.86 (+0.25%)
     

  • CMC Crypto 200

    1,394.31
    +11.73 (+0.85%)
     

  • GOLD FUTURES

    2,343.60
    +5.20 (+0.22%)
     

  • RUSSELL 2000

    1,976.58
    -18.85 (-0.94%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,556.21
    -156.54 (-1.00%)
     

  • VOLATILITY

    16.28
    +0.31 (+1.94%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

COVAXX to Participate in Opening Keynote Panel with FDA and WHO experts on SARS-CoV-2 at the World Vaccine & Immunotherapy Conference West Coast December 1, 2020

Newsfile Corp.
·1 min read

Hauppauge, New York--(Newsfile Corp. - November 30, 2020) - COVAXX, a U.S. company developing a synthetic multitope peptide-based vaccine to fight COVID-19, today announced that Chief Scientific Officer, Farshad Guirakhoo, Ph.D. will participate in the Opening Keynote panel discussion, "SARS-CoV-2 - We have a vaccine-what now?" at the virtual World Vaccine & Immunotherapy Conference West Coast on Tuesday, December 1, at 12:00 pm PST.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • COVAXX's CSO, Farshad Guirakhoo, Ph.D., to participate in keynote panel about COVID vaccines on Dec. 1, 2020

Click image above to view full announcement.

ADVERTISEMENT

Contacts:

Ignacio Guerrero-Ros, Ph.D.
(646) 942-5604
Ignacio.Guerrero-Ros@russopartnersllc.com

Diane Murphy
(310) 658.8756
diane@covaxx.com

David Schull
(212) 845-4271
David.Schull@russopartnersllc.com

Source: COVAXX

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69178